Atopic dermatitis awareness is again at the center of a Sanofi and Regeneron skin health campaign.

GSK just inherited its biggest threat to Nucala in the form of a new AZ rival. But the British drugmaker says it’s down for some marketplace battling.

Calling all digital entrepreneurs: Johnson & Johnson is looking for creative tech skincare solutions in its Digital Beauty QuickFire Challenge.

Pfizer’s old dog Sutent has shown it has one more trick to perform as a renal cancer treatment before being passed up by the new breed of I-O drugs.

Eli Lilly faces allegations it ran a "multi-tiered kickback scheme" to pump up sales of key diabetes drugs.

In just a few years, pharma's top launches of 2014 have amassed huge sales and reshaped treatment—and they're now among the biggest launches ever.

Rare disease biotech Ultragenyx has its first FDA nod in Mepsevii, an enzyme therapy expected to carry a high price to treat a tiny group of patients.

AstraZeneca is about to find out whether its third-to-market respiratory biologic can stand out from a crowd that includes rivals GSK and Teva.